AC
MYGN icon

Allstate Corporation’s Myriad Genetics MYGN Stock Holding History

Allstate Corporation’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-16,416
Closed -$453K – 699
2021
Q4 		$453K Buy
16,416
+5,451
+50% +$158K 0.01% 688
2021
Q3 		$354K Buy
+10,965
New +$364K 0.01% 587

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Allstate Corporation's MYGN Position: Q1 2022 in Review

Allstate Corporation sold out of Myriad Genetics (MYGN) in Q1 2022, closing a stake of 16,416 shares — an estimated $453K sold.

Allstate Corporation first reported a position in MYGN in Q3 2021 and held it in 2 quarters. The position peaked at $453K in Q4 2021. 205 funds tracked by Wall St. Rank hold MYGN as of Q1 2022.

  • Allstate Corporation reported no remaining Myriad Genetics position as of Q1 2022 after selling out during the quarter.
  • Allstate Corporation sold 16,416 Myriad Genetics shares in Q1 2022, an estimated $453K.
  • Allstate Corporation first reported a position in Myriad Genetics in Q3 2021 and held it in 2 quarters.
  • Allstate Corporation's Myriad Genetics position peaked at $453K in Q4 2021.
  • 205 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2022.

Based on Allstate Corporation's 13F filing for Q1 2022, filed 16 May 2022.